C118P: Mepolizumab Biosimilar, Human IL-5 Monoclonal Antibody

Catalog No.: C118P | **Product Name:** Mepolizumab Biosimilar, Human IL-5 Monoclonal Antibody

The research grade Mepolizumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

PRODUCT SPECIFICATIONS

Catalog No.	C118P
Product Name	Mepolizumab Biosimilar, Human IL-5 Monoclonal Antibody
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	Interleukin-5; IL-5; T-cell replacing factor; TRF; EDF
Summary	Recombinant Humanized IgG1 kappa Monoclonal Antibody.
Isotype	Human IgG1 kappa.
Source/Host	The anti-human IL-5 monoclonal antibody mepolizumab biosimilar was produced in mammalian cells.
Specificity/Sensitivity	The in vivo grade mepolizumab biosimilar specifically binds to the IL-5 protein.
Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by mepolizumab.
Form Of Antibody	0.2 μM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin	< 1 EU per 1 mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The Mepolizumab Biosimilar, Human IL-5 Monoclonal Antibody is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	The research grade Mepolizumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

REFERENCES & BACKGROUND

What is mepolizumab biosimilar research grade? Mepolizumab (trade name Nucala) is a humanized IgG1 kappa monoclonal antibody that targets interleukin-5 (IL-5). IL-5 is the major cytokine responsible for the growth, differentiation, recruitment, activation, and survival of eosinophils. By binding to IL-5, mepolizumab prevents its interaction with the alpha chain of the IL-5 receptor complex expressed on the eosinophil surface, thereby reducing the production and survival of eosinophils. Mepolizumab is indicated for the add-on maintenance treatment of severe asthma with an eosinophilic phenotype, eosinophilic granulomatosis with polyangiitis (EGPA), hypereosinophilic syndrome (HES), and chronic rhinosinusitis with nasal polyps. Mepolizumab biosimilar uses the same protein sequences as the therapeutic antibody mepolizumab.